key: cord-0878881-topuw1i0
authors: Bauer, Lisa; Laksono, Brigitta M.; de Vrij, Femke M.S.; Kushner, Steven A.; Harschnitz, Oliver; van Riel, Debby
title: The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2
date: 2022-03-03
journal: Trends Neurosci
DOI: 10.1016/j.tins.2022.02.006
sha: 7617f2bdd3d5d0c682c03dd314253630be051fc4
doc_id: 878881
cord_uid: topuw1i0

SARS-CoV-2 infection is associated with a diverse spectrum of neurological complications in the acute and post-acute stages. The pathogenesis of these complications is complex and dependent on many factors. For accurate and consistent interpretation of experimental data in this fast-growing field of research, it is essential to use terminology consistently. In this article, we outline the distinctions between neuroinvasiveness, neurotropism, and neurovirulence. Additionally, we discuss current knowledge of these distinct features underlying the pathogenesis of SARS-CoV-2-associated neurological complications. Lastly, we briefly discuss the advantages and limitations of different experimental models, and how these approaches can further be leveraged to advance the field.

CNS cell types are highly diverse and comprised of many different subpopulations of neurons and non-neural cell types, with often distinct cell-intrinsic antiviral immunity [12] .

To understand how virus invasion and associated responses contribute to the pathogenesis of SARS-CoV-2-associated CNS diseases, it is important to distinguish between neuroinvasiveness, neurotropism, and neurovirulence (see Glossary). Unfortunately, these terms are not used consistently in the literature, leading to ambiguity of the conclusions across studies examining SARS-CoV-2 infection in the CNS. For this reason, we emphasize that these definitions should be used correctly, as defined in much of the long-standing literature in the field of neuroinflammation, and as summarized in the Glossary. In this context, we will discuss current knowledge of these different aspects underlying the pathogenesis of SARS-CoV-2 infection. For neuroinvasiveness and neurovirulence, we will focus on in vivo findings in humans and in experimental animal models, as the latter can provide more detailed insight into the temporal kinetics of a SARS-CoV-2 infection. In vitro studies will be included when neurotropism is discussed. Finally, we will discuss different in vivo and in vitro models that can be used to study neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2.

J o u r n a l P r e -p r o o f Journal Pre-proof Neuroinvasiveness Neuroinvasiveness refers to the ability of a virus to enter the peripheral nervous system or CNS.

Viruses can access the CNS through peripheral nerves and/or via the hematogenous route ( Figure 1 ). SARS-CoV-2 may enter the CNS through nerve endings of cranial nerves that innervate the respiratory tract, followed by axonal (either anterograde or retrograde) transport of the virus to the CNS. For hematogenous spread, the virus needs to spill over into the circulation (viremia) and subsequently cross the blood-brain-barrier (BBB) and/or bloodcerebrospinal fluid barrier (B-CSFB) [13, 14] .

The human respiratory tract, which is the primary replication site for SARS-CoV-2, is innervated by several cranial nerves (CN). The nasal cavity is innervated by the trigeminal nerve (CN V) and olfactory nerve (CN I); the upper respiratory tract by the facial (CN VII) and glossopharyngeal (CN IX) nerve; and the lower respiratory tract by the vagus nerve (CN X). There is increasing evidence that SARS-CoV-2 can use these cranial nerves to enter the CNS. Studies in humans and experimental animal models have provided evidence for virus invasion along the olfactory nerve by the detection of viral RNA or viral protein in sustentacular cells in the olfactory mucosa and, to a lesser extent, in olfactory sensory neurons (OSNs) (Figure 1 ) (discussed in more details in the section 'neurotropism') [8, [15] [16] [17] [18] [19] [20] . Whether SARS-CoV-2 is transported to the CNS transaxonally in OSNs or through diffusion via channels formed by olfactory ensheathing cells along the olfactory nerve remains debated. CNS invasion via the trigeminal nerve has been suggested in humans, as viral RNA has been detected in the trigeminal ganglion, suggesting virus spread via nerve endings to the soma of sensory neurons [16, [21] [22] [23] [24] . Evidence in humans for virus invasion through the vagus nerve has been provided by the detection of SARS-CoV-2 protein by immunohistochemistry in vagus nerve fibers [23, 25] . To our knowledge, no evidence for virus invasion via the glossopharyngeal or facial nerves has yet been reported.

SARS-CoV-2 is able to disseminate into the circulation, which could result in subsequent virus spread through the BBB or B-CSFB into the CNS. In COVID-19 patients, SARS-CoV-2 viral RNA [26] [27] [28] and viral particles [26] have been detected in the blood or serum (situations referred to J o u r n a l P r e -p r o o f Journal Pre-proof as RNAemia and viremia, respectively). The BBB, among its various functions, protects neural tissues from pathogens in the circulation. There is currently no conclusive evidence on whether SARS-CoV-2 can cross the BBB, but SARS-CoV-2 antigens have been detected in small vessel endothelial cells in humans and animal studies [16, 29, 30] . In addition, in vivo damage of the basement membrane of the BBB has been observed in mice and hamsters after SARS-CoV-2 infection [31] , and in in vitro BBB models SARS-CoV-2 can cross the endothelial cell layer [31, 32] . Whether this results in virus spread into the brain parenchyma in vivo is unknown.

SARS-CoV-2 infection of choroid plexus epithelial cells, and subsequent invasion into the CNS via the B-CSFB has been suggested in a number of studies [31, 33] . Altogether, evidence for virus invasion into the CNS via the BBB or B-CSFB is limited, but studies suggest that such invasion might occur at least in a subset of patients.

The route of virus entry into the CNS likely influences the disease manifestations. For example, Bell's palsy, which some studies have suggested to be associated with SARS-CoV-2 infection, could be the result of virus invasion via the facial nerve [34] ; virus infection along the olfactory nerve could result in anosmia [16] [17] [18] 35] ; and spread to the CNS via viremia and/or infection of brain microvascular endothelial cells may result in intracerebral hemorrhage [36, 37] . Whether each of these infection routes is indeed directly associated with specific disease manifestation requires more in-depth studies. A major goal for future work is to obtain a deeper understanding of the frequency and routes of CNS invasion by SARS-CoV-2, as well as how these potential routes of entry contribute to the observed diversity of CNS manifestations (see Outstanding Questions).

Neurotropism refers to the ability of a virus to infect and replicate in cells of the nervous system. Several reports investigated the cell tropism of SARS-CoV-2, including studies that examine its tropism along the olfactory nerve. The olfactory mucosa consists of OSNs, [16, 17] , and in experimentally inoculated hamsters, mice and ferrets ( Figure   1 ) [17] [18] [19] 29, [38] [39] [40] . A few studies have found evidence for SARS-CoV-2 infection in OSNs early after inoculation in experimentally inoculated hamsters [17, 18, 40] or COVID-19 patients with chronic anosmia [17] . However, in other studies, virus antigen in OSNs was not detected [20, 29] . Whether these inconsistencies are related to differences in the time post-infection, or reflect pathophysiological heterogeneity among individuals is not fully understood.

Once inside the CNS, the virus is exposed to different cell types, including various subtypes of neurons, glial lineage cells (oligodendrocyte precursor cells, oligodendrocytes, astrocytes, and ependymal cells), microglia, cells of the choroid plexus, and neurovascular cells including vascular endothelial cells and pericytes ( Figure 2 ). The receptor ACE2 is expressed in several brain locations including the choroid plexus and olfactory bulb [41] [42] [43] . Cell types expressing ACE2 include excitatory and inhibitory neurons, and some non-neuronal cells such as astrocytes, oligodendrocytes, and endothelial cells [41, 44] . In humans, autopsies revealed SARS-CoV-2 antigens in the brain parenchyma and cortical neurons of some patients, while SARS-CoV-2 viral RNA has been detected in the substantia nigra [16, 29] . Additionally, animal studies suggest that dopaminergic neurons and, to a lesser extent, cortical neurons, microglia, and astrocytes are susceptible to SARS-CoV-2 infection [29, 45, 46] . Human pluripotent stem cell (hPSC)-derived 2D cultures and 3D organoids (models reviewed in [47] ) have been used to investigate the cell tropism of SARS-CoV-2 in vitro [48] . In general, studies suggest that different cell types, including dopaminergic neurons, cortical neurons, brain microvascular endothelial cells and choroidal epithelial cells are susceptible to SARS-CoV-2 infection, but among these different cell types there are differences in the permissiveness for SARS-CoV-2 (the ability to produce progeny virus) [29, [49] [50] [51] [52] [53] [54] [55] [56] . Studies in choroid plexus organoids show that choroidal epithelial cells are permissive for SARS-CoV-2 infection [50, 51, [55] [56] [57] [58] [59] . Currently, there is no in vivo or in vitro evidence, to our knowledge, for productive infection of neural progenitor cells with SARS-CoV-2, and some studies provided evidence arguing against this possibility [52, 53, 56] .

In humans and in animal models, SARS-CoV-2 virus or virus antigen has been detected in endothelial cells of the brain [16] . Evidence for productive infection of primary endothelial cells derived from different organs is scarce, and in vitro studies show that SARS-CoV-2 infects endothelial cells only when ACE2 is artificially overexpressed [60, 61] . In principle, abortive infection (cell infection without follow up production of progeny virus) of endothelial cells [60, 61] or pericytes [62] could weaken the BBB, which could make it more susceptible for virus invasion or result in microvascular complications.

Among the studies examining SARS-CoV-2 infection of CNS cell types, most studies have shown that infection is restricted to a subset of cells, and that virus replication is often inefficient or even abortive. Despite this inefficient or abortive replication, infection is likely associated with changes in cellular functioning and responses. One of the mechanisms underlying altered cellular function following SARS-CoV-2 infection involves cellular senescence, which may affect both infected and bystander cells [45] . [63] [64] [65] [66] [67] , as well as loss of gray matter in the parahippocampal gyrus, the lateral orbitofrontal cortex, and the insula [67] .

Anosmia has been often associated with SARS-CoV-2 infection, at least with the initial variants of the virus, but the underlying pathology is not fully understood. The mechanisms underlying olfactory dysfunction may involve a complex and possibly long-lasting interplay of dysregulated immune responses in the olfactory mucosa and the olfactory bulb, as well as virus-induced lesions along the olfactory tract [18, 35] . In hamsters and mice, there is evidence for focal destruction of the olfactory mucosa, associated with an influx of inflammatory cells [19, 68, 69] .

Autopsy findings from COVID-19 patients found focal atrophy and infiltrating CD45 + leukocytes, CD4 + T cells, CD8 + T cells, and activated macrophages in the olfactory mucosa in a subset of patients [16, 17, 70, 71] .

Several studies have found evidence for CNS inflammation after SARS-CoV-2 infection. In humans, activated microglia were found in the olfactory bulb, midbrain (specifically, in the substantia nigra), hindbrain, dorsal motor nucleus of the vagus nerve, and the pre-Bötzinger complex in the medulla [72] . Furthermore, multifocal microgliosis and astrogliosis were reported in elderly patients [73] , although it could not be ruled out that these were associated with host factors [74] . Perivascular and parenchymal infiltrations of CD8 + cytotoxic T cells and macrophages have been reported post-mortem in COVID-19 patients and in intranasally inoculated mice at 6 days post-inoculation [62, [73] [74] [75] . Extensive inflammatory responses, such as astrogliosis, activation of microglia, and perivascular cuffing of T cells, were detected postmortem in both white and gray matter of patient brains regardless of their COVID-19 disease severity, a finding that appeared most pronounced in the cranial medulla oblongata and olfactory bulb [76] . Furthermore, evidence for acute hypoxic injury was observed in the [66, 79, 80] . Post mortem analyses on the CNS from patients that died of COVID-19 showed thinning of the basal lamina of endothelial cells and congested blood vessels with fibrinogen leakage, suggestive of microhemorrhages [16, 72] . Studies in COVID-19 patients and in animal models, including hamsters and K18-hACE2 mice, suggest that SARS-CoV-2 infection of brain vascular endothelial can lead to endothelial cell death and formation of string vessels in the cortex [30] . Additionally, perivascular infiltration of CD3 + , CD8 + T cells and macrophages, as well as the presence of hypertrophic astrocytes, activated microglia were detected [16, 17, 70, 71] .

The underlying neurovirulent pathologies of SARS-CoV-2 are diverse, and it is plausible that there is not one sole mechanism triggering these changes. Furthermore, it is likely that host factors like sex and age, or underlying diseases, complicate the picture of the diverse CNS complications associated with SARS-CoV-2 infection (see Outstanding Questions).

Studying the pathogenesis in human samples and human post-mortem tissue can reveal important insights into neurological complications associated with SARS-CoV-2, albeit with limitations. First, samples are collected after disease onset, so the early phases of the infection are not captured in this approach. Second, sequential sampling is often difficult, and in most cases (except post-mortem studies) samples can only be taken from the CSF or from outside the CNS. Lastly, there is substantial heterogeneity in human cohorts, including differences in age, sex, comorbidities, and immune status. Complementing studies in humans, in vivo animal models and in vitro hPSC approaches can assist in elucidating pathological mechanisms during J o u r n a l P r e -p r o o f the acute and post-acute stages of the disease as well as various aspects of virus-host cell interactions. However, extrapolating from animal data or human cellular modeling data to human clinical situations comes with limitations which should be carefully considered.

Several animal models have been established to study the pathogenesis of SARS-CoV-2 infection in vivo, including models in mice, hamsters, and to a lesser extent ferrets and nonhuman primates (NHPs) [81, 82] . Mice are not naturally sensitive to SARS-CoV-2 replication, but transgenic expression of human ACE2 or transduction of mice with adenovirus or adenoassociated viruses expressing humane ACE2 sensitizes mice to SARS-CoV-2 infection. Despite the fact that the tissue and cell ACE2 expression in these models differs from humans, these mice models have been used to study the effect of virus replication in the brain [81] [82] [83] [84] and inflammation induced changes in the brain [75, 85, 86] . Although the observations cannot directly be extrapolated to humans, they provide important insights into the different mechanisms that could contribute to the large spectrum of neurological complications following SARS-CoV-2 infection. Experimental inoculation of ferrets or NHP with SARS-CoV-2 generally result in only mild respiratory disease, with limited evidence for CNS invasion [83, 87, 88] . However, these models could potentially shed light on changes in the CNS after a mild SARS-CoV-2 infection in the acute and post-acute stage [89] .

Experimental inoculation of hamsters results in more severe respiratory disease, with virus being detected in extrapulmonary tissues including the CNS. Studies in Syrian hamsters detected viral RNA in the CNS as well as inflammation and changes in the neurovascular system [30, 90] . Although in hamster studies the Syrian hamster has been used most frequently, it was recently shown that in Roborovski Dwarf hamsters, inbred hamsters, transgenic hamster expressing human ACE2, and obese hamsters SARS-CoV-2 infection resulted in more severe disease, and systemic spread including virus spread to the CNS [91] [92] [93] [94] .

The different in vivo models enable studies on the neuroinvasiveness, neurotropism and neurovirulence of SARS-CoV-2 during the course of infection, including before disease onset and the post-acute phase. In our opinion, these models provide a unique opportunity to study the impact of virus dose, sex, age, obesity, as well as risk factors and comorbidities on the pathogenesis in the acute and post-acute stage in a controlled manner, which is challenging in humans. However, it should be realized that there are differences in the course of disease among the in vivo models. Therefore, it is important to choose the most suitable model for specific research questions.

hPSC-based models are ideal tools to investigate the interaction between SARS-CoV-2 and cells of the CNS and peripheral nervous system (PNS). These models, either 2D or 3D, allow investigating neural and non-neural cells from different CNS regions, which are known to display extensive heterogeneity in their gene expression profiles, functionality, and immunological status. Moreover, hPSC-derived sensory neurons can be used to address the question of whether and which sensory neuron subtypes are susceptible to SARS-Co-2 infection, and whether they facilitate transaxonal transport. Due to their scalability, hPSC-based models are particularly well-suited for large-scale compound screening and whole-genome screens to dissect virus-host interactions.

When studying SARS-CoV-2 infection in different cells and/or tissues it is important to differentiate between susceptibility or permissiveness. Susceptibility can be shown by the detection of viral antigens (using immunofluorescence or immunohistochemistry) or by the detection of viral RNA (using in situ hybridization, qPCR, or RNAseq). When these analyses are performed on tissue sections from in vivo models, the location of virus antigen can directly be associated with histological lesions. These assays, nonetheless, require the use of adequate controls, such as isotype and omission negative controls and preferentially the inclusion of two methods to ensure true detection of infection. Ideally, permissiveness is determined in vitro by 

Currently available data show that SARS-CoV-2 has neuroinvasive potential, that its neurotropism is limited, and that it can be neurovirulent in at least a subgroup of patients. This concurs with observations from the clinic, where the impact of SARS-CoV-2-associated CNS complications seems limited in the acute phase, but more prominent in the post-acute phase.

Reports of severe disease in the acute phase, such as encephalitis exist, but these are rare compared to the number of people infected [95, 96] . However, the number of patients suffering from SARS-CoV-2-associated CNS impairments in the post-acute phase, which are part of the wide spectrum of complications associated with long COVID, can be up to 30-60% of the patients [5] [6] [7] .

CNS complications observed during the acute and post-acute stage of SARS-CoV-2 infection are diverse, which might be related, at least in part, to host factors, co-morbidities, immune status of the host, virus variants, or other variables [97] [98] [99] . Host factors or co-morbidities that affect the risk to develop severe disease from COVID-19 include age, sex, metabolic status, or preexisting neurological conditions. Whether each of these factors influences the development of CNS disease, and if so how, is not fully understood. In addition, potential differences among SARS-CoV-2 variants in terms of their neuroinvasiveness, neurotropism, or neurovirulence remain to be further investigated. Potential differences among SARS-CoV-2 variants in terms of their neuroinvasiveness, neurotropism, or neurovirulence remain to be further investigated, but it has already been shown that SARS-CoV-2 variants differ in the pathogenesis of respiratory disease [ [100, 101] . The possible emergence of future variants could add additional complexity J o u r n a l P r e -p r o o f to the issue. Furthermore, the risk for developing CNS diseases after infection with SARS-CoV-2 might change after vaccination or prior SARS-CoV-2 infection. It has already been shown that vaccination partly protects against development of long COVID [102] . Other variables that possibly influence the development of CNS disease include for example the infection dose and primary replication site of the virus [75] . Respiratory viruses can access the CNS via peripheral nerves, including cranial nerves that innervate the respiratory tract, or via the hematogenous route. For coronaviruses (e.g. HCoV-OC43, -229E and SARS-CoV-1) evidence suggests that virus entry into the CNS occurs preferentially via the olfactory nerve [106, 107] . Influenza A viruses can use both the olfactory nerve and other cranial nerves that innervate the respiratory tract, such as the trigeminal [108] and vagus nerves [109] . Enterovirus-D68 is thought to use peripheral nerves by transaxonal transport in motor neurons [110, 111] .

Hematogenous virus spread into the CNS can occur via different mechanisms. For example, respiratory syncytial virus and measles virus can infect blood leukocytes, which transmigrate over the blood brain barrier into the CNS (acting as a "Trojan Horse") [112] . Hematogenous spread to the brain might also occur in the case of coronaviruses. While this has not been studied extensively, different strains of coronaviruses have been shown to infect myeloid cells, and cell-free virus has been detected in the blood (viremia) [113, 114] . 

Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis

Neurologic manifestations in hospitalized patients with COVID-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

Mild or Moderate Covid-19

2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Long COVID: understanding the neurological effects

Long COVID in a prospective cohort of home-isolated patients

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review

Comprehensive Review on Neuro-COVID-19 Pathophysiology and Clinical Consequences

Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions

Human iPSC-derived trigeminal neurons lack constitutive TLR3-dependent immunity that protects cortical neurons from HSV-1 infection

Neurotropic virus infections as the cause of immediate and delayed neuropathology

Virus infections in the nervous system

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters

Non-cell autonomous disruption of nuclear architecture as a potential cause of COVID-19 induced anosmia

Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters

Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb

SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: Implications for spillback to New World rodents

Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

Trigeminal neuralgia as the sole neurological manifestation of COVID-19: A case report

Brainstem neuropathology in two cases of COVID-19: SARS-CoV-2 trafficking between brain and lung

SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes

SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes

Neuroinvasion of SARS-CoV-2 in human and mouse brainNeuroinvasion of SARS-CoV-2 in humans and mice

The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells

SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration

The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2

SARS-CoV-2 infection of the central nervous system in a 14-monthold child: A case report of a complete autopsy

Incidence of Bell Palsy in Patients With COVID-19

SARS-CoV-2 infection results in lasting and systemic perturbations post recovery, Microbiology

Intracerebral hemorrhage in COVID-19: A narrative review

Intracerebral Hemorrhage in Patients With COVID-19: An Analysis From the COVID-19 Cardiovascular Disease Registry

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection

Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters

The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains

SARS-CoV-2 Infectivity and Neurological Targets in the Brain

SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain

Single-cell RNA sequencing analysis of SARS-CoV-2 entry receptors in human organoids

SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence

Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection

Human stem cell models to study host-virus interactions in the central nervous system

Neurotropic Effects of SARS-CoV-2 Modeled by the Human Brain Organoids

SARS-CoV-2 targets neurons of 3D human brain organoids

Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium

SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids

Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2-and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models

Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2

SARS-CoV-2 targets glial cells in human cortical organoids

ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response

SARS-CoV-2 infects human neural progenitor cells and brain organoids

SARS-CoV-2 targets glial cells in human cortical organoids

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus

Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses

Endothelial cells are not productively infected by SARS-CoV-2

Infection of Brain Pericytes Underlying Neuropathology of COVID-19 Patients

Anosmia in COVID-19 Associated with Injury to the Olfactory Bulbs Evident on MRI

Bilateral transient olfactory bulb edema during COVID-19-related anosmia

COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms. SN Compr

COVID-19-associated Diffuse Leukoencephalopathy and Microhemorrhages

Brain imaging before and after COVID-19 in UK Biobank

Ultrastructural Evidence of Direct Viral Damage to the Olfactory Complex in Patients Testing Positive for SARS-CoV-2

Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia

Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia

Inflammatory olfactory neuropathy in two patients with COVID-19

Microvascular Injury in the Brains of Patients with Covid-19

Neuropathology of patients with COVID-19 in Germany: a postmortem case series

Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review

Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Neuropathological Features of Covid-19

Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Advances and gaps in SARS-CoV-2 infection models

Animal models for COVID-19

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice

Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys

COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters

Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2

Western diet increases COVID-19 disease severity in the Syrian hamster

Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2

The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection

Encephalitis associated with the SARS-CoV-2 virus: A case report

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes

Host genetic factors determining COVID-19 susceptibility and severity

Genome-Scale Identification of SARS-CoV-2 and Pancoronavirus Host Factor Networks

Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between

Understanding enterovirus D68-induced neurologic disease: A basic science review

Neurologic Alterations Due to Respiratory Virus Infections. Front

Neuropathogenic human coronaviruses: A review

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Identification of viruses in patients with postviral olfactory dysfunction

The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice

In vitro demonstration of neural transmission of avian influenza A virus

Contemporary Circulating Enterovirus D68 Strains Infect and Undergo Retrograde Axonal Transport in Spinal Motor Neurons Independent of Sialic Acid

Causation of Acute Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 Infected Mice Deficient in Interferon αβ/γ Receptor Deficient Mice

Impaired learning resulting from Respiratory Syncytial Virus infection

Activation of human monocytes after infection by human coronavirus 229E

Neuroinvasion by Human Respiratory Coronaviruses

• Which route(s) can SARS-CoV-2 use to enter the CNS, and how does the route of entry contribute to the subsequent virus spread and/or disease outcomes?

• What is the frequency of SARS-CoV-2 entry into the CNS? • What are the cell-specific responses in the CNS after SARS-CoV-2 infection? • What are the different cell-autonomous mechanisms that can lead to the neurovirulence of SARS-CoV-2 in the acute and post-acute phases?

sex and age), or underlying co-morbidities (e.g. diabetes, obesity) contribute to the severity of acute and post-acute SARS-CoV-2-associated neurological complications, and if so, how?

• What are risk factors for the development of acute and post-acute SARS-CoV-2-associated CNS disease?

• Are there differences among SARS-CoV-2 variants, in particular variants of concern, in their neuroinvasiveness

• Is SARS-CoV-2 unique among respiratory viruses in its ability to invade the CNS or in the frequency it does so? Is it unique in its ability infect certain cell types of the CNS, or in its ability to cause specific CNS complications?

• Can infection with SARS-CoV-2 exacerbate prior underlying neurodegenerative or neuropsychiatric diseases?